← Leaderboards
Jennifer Caswell-Jin
Stanford University
$1,127,590
Attributed
$1,127,590
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $225.5K · FY2020–24$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,127,590 · 1
By mechanism
K08$1,127,590 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Joseph C Wu$80,370,369
- Sylvia Katina Plevritis$44,733,712
- Harry Bernard Greenberg$91,083,131
- Mark M Davis$39,722,191
- Robert S Negrin$29,816,136
Others in their field
Other Emerging Leaders on “Data Set”
- Joel A Lipkin · Four Points Technology, Llc$182,936,915
- Terry Drinkwine · Carahsoft Technology Corporation$93,011,563
- Leonard Freedman · Leidos Biomedical Research, Inc.$92,966,200
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Martha Hering · Westat, Inc.$57,098,843
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
Data SetAffectAutomobile DrivingApplications GrantsAreaBioinformaticsBiologyBiomarker DevelopmentBiopsyAwardBreast Cancer GenomicsCancer EtiologyCancer SubtypesCareerCareer DevelopmentCategoriesCcnd1 GeneCdk4 GeneCessation Of LifeCharacteristicsBreastClinical TrialsCohortDesign
Grant awards (5)
Integrative subtyping to improve therapeutic options for metastatic hormone receptor-positive breast cancer$225,518
K08 · FY2024 · CA · contact PI
Integrative subtyping to improve therapeutic options for metastatic hormone receptor-positive breast cancer$225,518
K08 · FY2023 · CA · contact PI
Integrative subtyping to improve therapeutic options for metastatic hormone receptor-positive breast cancer$225,518
K08 · FY2022 · CA · contact PI
Integrative subtyping to improve therapeutic options for metastatic hormone receptor-positive breast cancer$225,518
K08 · FY2021 · CA · contact PI
Integrative subtyping to improve therapeutic options for metastatic hormone receptor-positive breast cancer$225,518
K08 · FY2020 · CA · contact PI